Marc Faraggi

Investigators Research Group (United States) — United States

Medicine · Health Sciences

32h-index3.6kcitations193works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac Imaging and Diagnostics(58), Cell Adhesion Molecules Research(33), Glioma Diagnosis and Treatment(26), Medical Imaging Techniques and Applications(26), Caveolin-1 and cellular processes(22)

Publications189 total

Figure S2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S8 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S7 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S7 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S8 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Table S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
FIGURE 6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
Figure S3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Dominique Le Guludec(17), Rachida Lebtahi(13), Doumit Daou(11), Philippe Gabríel Steg(9), Florent Hugonnet(6), Michel Slama(5), D Le Guludec(5), Nicolas Delahaye(5), Daniel Czitrom(5), Patrick Assayag(5), M Mignon(4), Jean‐Pierre Laissy(4), Laurent J. Feldman(4), Benoît Paulmier(4), R Gourgon(4), Éric Brochet(4), Alain Cohen‐Solal(4), Jean‐Michel Juliard(3), D. Vilain(3), Daniel Karila‐Cohen(3)